1 min read

October Image of the Month

YOU BE THE PATHOLOGIST!

What are these (*) large cells, considered to be one of the main inflammatory cells at the tissue-device interface? (Scale bar: 25 µm)

ANSWER

 

These are multinucleated giant cells!

 

Multinucleated giant cells are the dominant responders to biomaterial implantation. Other inflammatory cells can also be observed (lymphocytes, macrophages, plasma cells). The evaluation of cell type and severity of the inflammation are critical in assessment of local tolerance by medical device pathologists.

 

They are derived from « frustrated » macrophages which are unable to degrade a foreign body and so fuse to increase their phagocytosis ability. They are expected when foreign material is implanted, but some materials elicit an even greater multinucleated giant cell response than others. For example, sutures, such as are present in the field shown, are known to elicit a powerful inflammatory response.

 

H&ES, Original magnification: x40, scale bar: 25 μm.

*: Multinucleated giant cell

 

This histopathology image is one example from the comprehensive suite of Pathology Services offered by Veranex Preclinical Services’ in-house team of Veterinary Pathologists.

 

If you are interested in learning more about our preclinical research and pathology services, we encourage you to get in touch with us. We would be delighted to discuss your specific needs and plans.

 

2 min read

Reducing the 90% Recurrence Rate for Glioblastoma Treatment Through an Implantable Device for the Delivery of Stem Cells

Extending Patient Lifespan with LifeSTEM What is Glioblastoma? Gliomas are brain tumors that come in multiple forms ranging from low-grade,...

Read More

Recent Study Co-authored by Veranex Staff Highlights Cost-effectiveness of Home Non-invasive Ventilation in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom

By developing a cost-effectiveness model and associated manuscript for home non-invasive ventilation in patients with persistent hypercapnia after...

Read More

3 min read

CMS Proposes Changes to Part B Medicare Reimbursement for Physician-Administered Drugs Approved Under the 505(b)(2) Approval Pathway

The Centers for Medicare and Medicaid Services (CMS) intends to alter assignment of Healthcare Common Procedure Coding System (HCPCS) Level II...

Read More